Sooil Development’s Major Contract with Mediq: A Closer Look at the 300 Billion Won(20M USD) Deal

Sooil Development recently announced a significant new contract with Mediq, a major European medical device distributor. This four-year agreement is valued at 300 billion won. How did Sooil achieve this, and what does it mean for their future?

The Details of the Supply Contract

Sooil Development, a leading player in insulin pump technology, sealed a 300 billion won contract with Mediq, based in the Netherlands. Key aspects of the contract include:

• Partnering with Mediq over four years to expand their insulin pump technology across Europe.
• The deal was reached through Sooil’s collaboration with French AI diabetes treatment firm, Diabeloop.
• Combining Sooil’s technology and Diabeloop’s AI to create a robust diabetes treatment solution.

The agreement will distribute their product gradually beginning in Germany, followed by other countries including:

1. Netherlands
2. Luxembourg
3. Belgium
4. France
5. United Kingdom

Innovative Technology at the Core

The contract’s foundation is the Automated Insulin Delivery (AID) system, a tech fusion of Sooil’s pumps and Diabeloop’s AI algorithms. This collaboration signals a recognition of the system’s potential in the European market.

CEO Choi Subong hailed the agreement as a validation of their technology on the global stage. He emphasizes ongoing tech development to establish Sooil as a top insulin pump innovator.

Strategic Market Expansion

The contract with Mediq aligns with Sooil’s strategy to tap the vast European market. It’s part of the AID project’s rollout, aiming at widespread distribution.

• Initial shipments have successfully commenced to Germany.
• The focus remains on enhancing distribution channels in lucrative markets such as the UK and France.

Key Takeaways

This contract represents a transformative step for Sooil Development:

• Global Recognition: The deal with Mediq underscores European market confidence in Sooil’s tech, specifically within the diabetes management sector.
• Partnership Synergy: The joint venture with Diabeloop merges two cutting-edge technologies into a compelling diabetes management solution.
• Growth Trajectory: CEO Choi’s vision sets a course for Sooil to become a world leader among insulin pump manufacturers.

With the promise of robust partnerships and innovative tech, Sooil is poised to capture a larger share of the European healthcare market.